What are the odds of being harmed or killed by a counterfeit or substandard medicine?
Evidence quality 3.75/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 4/5
- D2 Source authority
- 3/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 4/5
- D6 Prose
- 4/5
- D7 Perception honesty
- 3/5
- D8 Caveat completeness
- 4/5
Lifetime probability · lifetime, subgroup
1 in 361
0.3% lifetime chance
Most people underestimate this.
range 1 in 667 to 1 in 182
≈ As likely as
Perceived
In high-income countries with stringent pharmaceutical regulation, the idea of receiving a fake or substandard medicine feels like a plot device from a thriller rather than a routine hazard. Pharmacies are licensed, supply chains are audited, and regulatory agencies pull defective batches within days. The mental model of a medicine simply not containing the drug on its label does not map onto everyday experience. In low- and middle-income countries the situation is categorically different: WHO estimates that 1 in 10 medical products in these settings is substandard or falsified, and the consequences are not merely inefficacy but death, particularly among children treated with fake antibiotics for pneumonia or counterfeit antimalarials for malaria.
Source: editorial intuition, not polled
Actual
~188,000 deaths per year globally from substandard or falsified medicines
global adults and children
Show derivation
Native rate: WHO-commissioned models estimate 72,000-169,000 child deaths per year from pneumonia caused by substandard/falsified antibiotics (University of Edinburgh model) and 116,000 (64,000-158,000) additional deaths from malaria caused by substandard/falsified antimalarials in sub-Saharan Africa (London School of Hygiene and Tropical Medicine model). A conservative combined estimate of ~188,000 deaths/yr is used, reflecting overlap between model ranges. The burden falls almost entirely on low- and middle-income countries (LMICs), where ~4 billion people live and where WHO estimates 1 in 10 medical products is substandard or falsified. Dividing by the at-risk population: 188,000 / 4,000,000,000 = 4.7e-5 annual rate. Lifetime conversion using the 59-year horizon: 1 - (1 - 4.7e-5)^59 = 0.00277. Uncertainty low bound uses 100,000 deaths (conservative floor accounting for model uncertainty and possible double-counting between the Edinburgh and LSHTM models) / 4B compounded 59 years = 1 - (1 - 2.5e-5)^59 = 0.0015. High bound uses 370,000 (169,000 + 158,000 plus ~15% for non-pneumonia/non-malaria categories) / 4B compounded 59 years = 1 - (1 - 9.25e-5)^59 = 0.0055. The true death toll is likely higher since these models cover only pneumonia and malaria, not cardiovascular, HIV/AIDS, or TB medicines. For adults in high-income countries with robust drug-quality regulation, personal risk is orders of magnitude lower.
Caveats: The 188,000 deaths estimate is derived from two disease-specific models covering…
The 188,000 deaths estimate is derived from two disease-specific models covering only pneumonia and malaria. The true global death toll from substandard and falsified medicines is almost certainly higher when cardiovascular drugs, HIV/AIDS antiretrovirals, tuberculosis medicines, and other therapeutic categories are included. The burden falls almost entirely on low- and middle-income countries with weak pharmaceutical regulatory systems. For any adult purchasing medicines through a regulated pharmacy in the US, EU, Japan, or other high-income country with robust drug-quality enforcement, the personal probability of encountering a substandard or falsified medicine is orders of magnitude lower than the global average. Online pharmacies operating outside regulatory oversight present a distinct and growing risk channel even in wealthy countries.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| LMIC adults (~4 billion) | 1 in 361 |
WHO estimates 1 in 10 medical products in LMICs is substandard or falsified |
| Global average (all adults) | 1 in 450 |
Diluted across 5B adults; misleading because risk concentrates in LMICs |
| High-income countries (regulated pharmacies) | 1 in 100,000 |
Effectively negligible; robust pharmaceutical regulation and supply-chain integrity |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Unsafe imported products
What are the odds of being harmed by an unsafe imported consumer product?
Childhood cancer diagnosis
What are the odds of a child being diagnosed with cancer before age 20?
COVID-19
What are the odds of dying from COVID-19 over the course of the pandemic and endemic era?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The World Health Organization estimates that 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified. Two disease-specific modelling exercises commissioned by WHO quantify part of the mortality cost: the University of Edinburgh estimates 72,000 to 169,000 children die each year from pneumonia because the antibiotics they received were substandard or fake, and the London School of Hygiene and Tropical Medicine estimates 116,000 additional deaths from malaria in sub-Saharan Africa attributable to substandard or falsified antimalarials. These two categories alone account for roughly 188,000 deaths per year, and the true toll is almost certainly higher since they exclude cardiovascular medicines, HIV/AIDS antiretrovirals, tuberculosis drugs, and every other therapeutic category in which quality failures also occur.
The perception gap runs in both directions depending on geography. In countries with stringent pharmaceutical regulation, the risk of encountering a counterfeit medicine is perceived as vanishingly small, and for regulated retail pharmacies it largely is. In low- and middle-income countries, however, the problem is systemic: weak regulatory capacity, fragmented supply chains, and insufficient quality-control infrastructure mean that a mother paying for her child’s antibiotics has no reliable way to verify that the product contains what its label claims. The WHO notes that antimalarials and antibiotics are the product categories most commonly reported as substandard or falsified, precisely the drugs most critical in settings with the highest infectious-disease burden. The result is a lethal feedback loop: the populations most dependent on effective medicines are the least protected from defective ones.
Where the number does not apply: any person purchasing medicines through a licensed pharmacy in a country with robust drug-quality regulation (the US, EU, Japan, Canada, Australia, and similar) is operating far outside the risk distribution that generates the 1-in-450 global lifetime figure. The primary residual risk in wealthy countries is the growing online pharmacy market, where products purchased outside regulated channels may bypass quality controls entirely. The 188,000 estimate is conservative and disease-limited; WHO itself uses the framing “hundreds of thousands” when describing the full scope of substandard-medicine mortality.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] World Health Organization — Substandard and falsified medical products — Fact sheet
Substandard and falsified medical products — Fact sheet- Statistic
At least 1 in 10 medicines in low- and middle-income countries are substandard or falsified; countries spend an estimated US$ 30.5 billion per year on such products- Excerpt
“"At least 1 in 10 medicines in low- and middle-income countries are substandard or falsified. Countries spend an estimated US$ 30.5 billion per year on substandard and falsified medical products." ”
- Source data from
- 2018-01-31
- Accessed
- 2026-04-26 · archived copy
- Calculation
- The WHO fact sheet has been restructured since the original access date. The detailed mortality models (University of Edinburgh pneumonia estimate of 72,000-169,000 deaths and LSHTM malaria estimate of 116,000 deaths) that previously anchored the native numerator are no longer present on this page. The 1-in-10 prevalence figure remains and establishes the scale of the problem in LMICs. The mortality estimates that underpin the 188,000 deaths/year figure were derived from earlier versions of this fact sheet and from the original research publications (Lancet Infectious Diseases, 2018). 188,000 / 5B = 0.0000376 annual rate, compounded over 59 years yields 0.00222.
- Independence
- Both sources are WHO publications drawing on the same underlying data and commissioned modelling studies. They are not independent data sources.
-
[2] World Health Organization — Substandard and falsified medical products — Health topics
Substandard and falsified medical products — Health topics- Statistic
More than 1 in 10 medicines in LMICs estimated substandard or falsified; up to 2 billion people lack access to necessary medicines- Excerpt
“"Up to two billion people around the world lack access to necessary medicines, vaccines, medical devices including in vitro diagnostics, and other health products, which creates a vacuum that is too often filled by substandard and falsified products. More than one in ten medicines in low- and middle-income countries are estimated to be substandard or falsified. No country remains untouched from this issue." ”
- Source data from
- 2020-06-01
- Accessed
- 2026-04-26 · archived copy
- Calculation
- This WHO health-topics page confirms the 1-in-10 prevalence framing and establishes the access-gap context (2 billion people lacking necessary medicines). The previously cited sub-URL with "hundreds of thousands" mortality framing is no longer accessible; the current page focuses on prevalence, impact, and WHO response. The mortality estimates underpinning the 188,000 figure are supported by the original Lancet Infectious Diseases publications rather than this summary page.
- Independence
- Same WHO data as source 1; different summary page, not an independent data source.
-
[3] The American Journal of Tropical Medicine and Hygiene — Renschler JP, Walters KM, Newton PN, Laxminarayan R — Estimated Under-Five Deaths Associated with Poor-Quality Antimalarials in Sub-Saharan Africa
Estimated Under-Five Deaths Associated with Poor-Quality Antimalarials in Sub-Saharan Africa- Statistic
Approximately 122,350 (IQR: 91,577–154,736) under-five deaths in 39 sub-Saharan African countries in 2013 were associated with consumption of poor-quality antimalarials, representing ~3.75% of all under-five deaths in those countries- Excerpt
“"An estimated 122,350 (interquartile range [IQR]: 91,577–154,736) under-five malaria deaths were associated with consumption of poor-quality antimalarials across 39 sub-Saharan African countries in 2013. This represented 3.75% of all under-five deaths in our sample of countries." ”
- Source data from
- 2015-06-01
- Accessed
- 2026-05-03 · archived copy
- Calculation
- Renschler et al. (2015) is the peer-reviewed modeling paper that independently quantifies child deaths from poor-quality antimalarials, using WHO child mortality data and antimalarial failure rate estimates for 39 sub-Saharan African countries. The 122,350 central estimate (IQR 91,577–154,736) is consistent with the LSHTM model figure of 116,000 (64,000–158,000) cited in WHO documentation; slight differences reflect model assumptions and reference year (2013 here vs. the WHO model's reference year). The overlapping uncertainty intervals confirm the same order-of-magnitude burden. This study covers malaria deaths only; combined with the Edinburgh University pneumonia model (72,000–169,000 deaths), the composite ~188,000 estimate is conservative. Used here as the independent peer-reviewed anchor confirming the malaria component of the native rate.
- Independence
- Independent of the WHO sources above: this is an academic modelling study published in a peer-reviewed journal (Am J Trop Med Hyg), authored by researchers at Princeton and Oxford (Paul N Newton of MORU/Oxford; Ramanan Laxminarayan of Princeton), using WHO child mortality inputs but applying an independent methodological framework to estimate attributable deaths.